WebMar 29, 2024 · SKYSCRAPER-02 is a global Phase III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq ® (atezolizumab) and … WebMar 30, 2024 · SKYSCRAPER-02 is a global Phase III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and …
A Study of Tiragolumab in Combination With …
WebJun 7, 2024 · Detailed data on this trial, called SKYSCRAPER-02, was revealed at the American Society of Clinical Oncology meeting on Sunday. "Based on these data, our conclusion is targeting TIGIT in extensive-stage small cell lung cancer does not appear to be therapeutically relevant," said Charles Rudin, a medical oncologist at Memorial Sloan … The trial enrolled 534 patients who were randomized 1:1 to receive either tiragolumab, an anti-T cell immunoreceptor with Ig and ITIM domain (TIGIT) immunotherapy agent, plus atezolizumab or placebo plus atezolizumab until disease progression, loss of clinical benefit, or unacceptable toxicity. find fmv of my home
FDA Grants Breakthrough Therapy Designation to Tiragolumab
WebApr 9, 2024 · The global, placebo-controlled, double-blinded SKYSCRAPER-02 trial enrolled patients with histologically or cytologically confirmed ES-SCLC who have not previously received systemic treatment. 2 To be eligible for enrollment, patients needed to have an ECOG performance status of 0 or 1, measurable disease per RECIST v1.1 criteria, … WebJan 19, 2024 · SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC … WebThis trial is comparing two treatments for non small cell lung cancer. The first treatment is atezolizumab and tiragolumab. The other treatment is durvalumab. It is for people with … findfocusgroups.com legit